Market capitalization | €277.33m |
Enterprise Value | €315.16m |
P/E (TTM) P/E ratio | 16.55 |
EV/FCF (TTM) EV/FCF | 15.37 |
EV/Sales (TTM) EV/Sales | 0.95 |
P/S ratio (TTM) P/S ratio | 0.83 |
P/B ratio (TTM) P/B ratio | 2.54 |
Dividend yield | 3.45% |
Last dividend (FY23) | €0.50 |
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
3 Analysts have issued a M1 Kliniken forecast:
3 Analysts have issued a M1 Kliniken forecast:
Jun '24 |
+/-
%
|
||
Revenue | 333 333 |
12%
12%
|
|
Gross Profit | 35 35 |
39%
39%
|
|
EBITDA | 28 28 |
56%
56%
|
EBIT (Operating Income) EBIT | 23 23 |
88%
88%
|
Net Profit | 17 17 |
164%
164%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
M1 Kliniken AG engages in the provision of medical services in the field of beauty sector. It operates through the Beauty and Trade segments. The Beauty segment focuses on medical-aesthetic beauty treatments and operations as well as the operation and provision of medical infrastructures for partner companies. The Trade segment sells pharmaceuticals and medical products in the cost-intensive therapeutic areas of oncology, HIV/AIDS, neurology, rheumatology, other chronic diseases, and aesthetic medicine. The company was founded in 2007 and is headquartered in Berlin, Germany.
Head office | Germany |
CEO | Patrick Brenske |
Founded | 2007 |
Website | www.m1-kliniken.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.